MedPath

Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Renin Angiotensin System Study (RASS/B-RASS)

Phase 2
Completed
Conditions
Type 1 Diabetes
First Posted Date
2005-09-02
Last Posted Date
2008-11-06
Lead Sponsor
Michael Mauer, MD
Target Recruit Count
285
Registration Number
NCT00143949
Locations
🇨🇦

Mt Sinai Hospital, University of Toronto (Clinical Ctr), Toronto, Ontario, Canada

🇨🇦

Montreal Childrens Hospital, McGill University (Clinical Ctr), Montreal, Quebec, Canada

🇨🇦

Royal Victoria Hospital, McGill University (Data Center), Montreal, Quebec, Canada

ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)

Phase 4
Completed
Conditions
High Blood Pressure
Interventions
First Posted Date
2005-09-01
Last Posted Date
2024-08-15
Lead Sponsor
Organon and Co
Target Recruit Count
367
Registration Number
NCT00140907

A Randomized, Double-blind, Parallel-group Assessment of the Safety and Efficacy of Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg (Micardis Plus) in Comparison With Losartan 50mg Plus Hydrochlorothiazide 12.5mg in Taiwanese Patients With Mild to Moderate Hypertension

Phase 3
Completed
Conditions
Hypertension
First Posted Date
2005-08-23
Last Posted Date
2013-11-19
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
31
Registration Number
NCT00133185
Locations
🇨🇳

Machay Memorial Hospital, Taipei, Taiwan

Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)

Phase 3
Completed
Conditions
Heart Failure
Interventions
First Posted Date
2004-08-27
Last Posted Date
2024-05-16
Lead Sponsor
Organon and Co
Target Recruit Count
3834
Registration Number
NCT00090259

Angiotensin II Blockade for Chronic Allograft Nephropathy

Phase 4
Completed
Conditions
Proteinuria
Kidney Disease
Interventions
First Posted Date
2003-09-05
Last Posted Date
2017-09-18
Lead Sponsor
University of Minnesota
Target Recruit Count
153
Registration Number
NCT00067990
Locations
🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

🇺🇸

Hennepin County Medical Center, Minneapolis, Minnesota, United States

Long Term Effects of Enalapril and Losartan on Genetic Heart Disease

Completed
Conditions
Hypertrophic Cardiomyopathy
Left Ventricular Hypertrophy
Myocardial Ischemia
First Posted Date
1999-11-04
Last Posted Date
2008-03-04
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
112
Registration Number
NCT00001534
Locations
🇺🇸

National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States

Study of Inherited Changes of Receptors Located on Blood Vessels

Phase 1
Completed
Conditions
Cardiovascular Disease
First Posted Date
1999-11-04
Last Posted Date
2008-03-04
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
200
Registration Number
NCT00001741
Locations
🇺🇸

National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath